Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Letters to the Editor

Antiobesity drug therapy

Taher Modarressi, MD
Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657; DOI: https://doi.org/10.3949/ccjm.88c.12001
Taher Modarressi
Diabetes & Endocrine Associates of Hunterdon, Hunterdon Medical Center, Flemington, NJ 08822
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor: The article by Mauer et al1 in the August issue is an excellent and comprehensive review of antiobesity pharmacologic therapy. The authors twice mention the positive impact of antiobesity medications in reducing blood pressure. I wish to highlight that the pre-semaglutide trials of antiobesity medications have generally shown an underwhelming blood pressure effect given the amount of weight loss. It is important for physicians to consider these data when counseling patients about the magnitude of expected benefits in initiation of antiobesity therapies. For example, in the CONQUER2 trial of phentermine-topiramate) and the SCALE3 trial of liraglutide, placebo-adjusted reductions of systolic blood pressure were approximately 3 mm Hg, and of diastolic blood pressure approximately 1 mm Hg. In CONQUER, the effect was minimally better when examining only the subgroup of patients with preceding hypertension, ie, approximately 4 mm Hg for systolic and 2 mm Hg for diastolic. The clinical relevance of these mild improvements may be less certain.

Of note, recent trials demonstrating more robust weight loss, such as those of semaglutide4 and tirzepatide,5 demonstrate more significant blood pressure reduction. It remains to be seen whether the improved effectiveness is simply due to increased weight loss, or whether other factors in the complicated pathophysiology of hypertension are being impacted.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Mauer Y,
    2. Parker M,
    3. Kashyap SR
    . Antiobesity drug therapy: an individualized and comprehensive approach. Clev Clin J Med 2021; 88(8):440–448. doi:10.3949/ccjm.88a.20080
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Gadde KM,
    2. Allison DB,
    3. Ryan DH, et al
    . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9774):1341–1352. doi:10.1016/S0140-6736(11)60205-5
    OpenUrlCrossRefPubMed
  3. ↵
    1. Pi-Sunyer X,
    2. Astrup A,
    3. Fujioka K, et al
    . A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373(1):11–22. doi:10.1056/NEJMoa1411892
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wilding JPH,
    2. Batterham RL,
    3. Calanna S, et al
    . Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384(11):989–1002. doi:10.1056/NEJMoa2032183
    OpenUrlCrossRefPubMed
  5. ↵
    1. Frías JP,
    2. Davies MJ,
    3. Rosenstock J
    . Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (12)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 12
1 Dec 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antiobesity drug therapy
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antiobesity drug therapy
Taher Modarressi
Cleveland Clinic Journal of Medicine Dec 2021, 88 (12) 657; DOI: 10.3949/ccjm.88c.12001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antiobesity drug therapy
Taher Modarressi
Cleveland Clinic Journal of Medicine Dec 2021, 88 (12) 657; DOI: 10.3949/ccjm.88c.12001
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • In Reply: Antiobesity drug therapy
  • Antiobesity drug therapy: An individualized and comprehensive approach
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Physician resistance to obesity pharmacotherapy
  • In Reply: Antiobesity drug therapy
Show more Letters to the Editor

Similar Articles

Subjects

  • Obesity
  • Preventive Care
  • Rheumatology
  • Vascular Medicine
  • Mental Health
  • Geriatrics
  • Endocrinology
  • Drug Therapy

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire